Allist Pharmaceuticals, Inc.

This study tests a new drug (JAB-21822) combined with cetuximab in people with advanced colorectal, small intestine, or appendiceal cancers that have a specific KRAS G12C mutation. Participants must have already tried at least one standard treatment. The goal is to see if the com…

This study tests an experimental oral drug called JAB-21822 (glecirasib) in people with advanced solid tumors that have a specific mutation in the KRAS gene (G12C). The trial aims to find the best dose and check if the drug is safe and can shrink tumors. About 315 adults whose ca…

This early-phase study tests a new oral drug, furmonertinib, in 30 people with advanced non-small cell lung cancer that has a specific EGFR exon 20 insertion mutation. Some participants have already tried other treatments, while others are newly diagnosed. The goal is to see if t…

This study tests a daily pill called furmonertinib in about 100 people with advanced non-small cell lung cancer that has a specific genetic change (EGFR exon 20 insertion). Participants must have already tried chemotherapy. The goal is to see if the drug shrinks tumors and how sa…